Business
Intensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer
Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage
About this update from Intensity Therapeutics, Inc.
[{"type":"text","content":"Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies \nSHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than 25 years of leadership experience in the biotechnology space, Mr. Talamo most recently served as Senior Vice President and Chief Financial Officer of HiberCell. Mr. John Wesolowski will remain as the Company's Principal Accounting Officer and Controller. \n\n \n \n \n \n \n \n\n \n\"I am delighted to welcome Joe to Intensity, his wealth of experience as a biotechnology executive and track record of success in leading financial operations will prove invaluable as we transition to a late-stage clinical company,\" said Lewis H. Bender, President and Chief Executive Officer of Intensity. \"I look forward to leveraging his versatile experience as we pursue our goal of treating solid tumors with our lead asset INT230-6.\"\nAs CFO, Mr. Talamo will develop and implement Intensity's financial strategies and lead financial reporting, finance corporate development, strategy and investor relations efforts while supporting the Company's overall business goals. Most recently, Mr. Talamo served as the CFO of HiberCell, building the financial and accounting function, and overseeing the evaluation of financing and strategic initiatives. Prior to HiberCell, Mr. Talamo spent ten years at Caladrius Biosciences, a clinical-stage biotech company dedicated to the development of cellular therapies, most recently serving as CFO. Before his tenure at Caladrius Biosciences, Mr. Talamo served as Vice President and Corporate Controller for OSI Pharmaceuticals. Mr. Talamo holds an MBA in Finance and a BBA in Accounting from Hofstra University. He also is a CPA registered in New York.\n\"I am thrilled to join Intensity at this pivotal time in the Company's evolution as i...